Integrated CDMO Capacity CorePharma operates four FDA- and DEA-registered facilities totaling 150,000 square feet with an annual capacity of up to 5 billion dosage units, enabling end-to-end development through commercial manufacturing under a single partner.

US Regulatory Strength With a proven track record of regulatory excellence and US-based operations, CorePharma offers reliable compliance and faster path from lab to patient across development, analytical, clinical and manufacturing functions.

End-to-End Solutions The company provides concept-to-commercial CDMO services, supporting early development, clinical manufacturing, packaging and launch readiness, reducing vendor handoffs and shortening timelines for clients.

Growth Ready Partner Industry-leading lead times and scalable capabilities position CorePharma as a viable partner for mid-size biotechs and emerging pharma players seeking timely scale-up in the US.

Cross Sell Opportunities CorePharma’s breadth across development, analytics, clinical and commercial manufacturing plus packaging creates opportunities to upsell integrated services to clients advancing from development to commercialization and to attract US-based full-service CDMO partnerships.